Acelyrin (Nasdaq: SLRN) has appointed Patricia Turney as chief technical operations officer.
Ms Turney most recently served as senior vice president, operations, at Arcutis Biotherapeutics (Nasdaq: ARQT) and has also held multiple senior positions at Amgen (Nasdaq: AMGN).
Earlier in her career at Amgen, she led R&D strategic operations initiatives for portfolio analysis, benchmarking, training and strategic planning.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze